Authors



Jacob J. Orme, MD, PhD

Latest:

Addressing Remaining Unmet Needs in mCRPC

Panelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize sequencing decisions and identify which patients will benefit most from specific therapies or combinations, particularly as the treatment landscape becomes increasingly complex.


Madison M. Wahlen

Latest:

Madison Wahlen on navigating the impact of the BCG shortage

“Some of the main implications for urologists is that the risk adapted utilization of BCG, which has been implemented as guidelines, should continue,” says Madison M. Wahlen.


Solaris Health

Latest:

Urologic Consultants has joined Solaris Health

Leading West Michigan practice now affiliated with nation’s largest urological healthcare management company


Daniel Kwon, MD

Latest:

Daniel Kwon, MD, discusses study’s impact on veteran access to germline testing for prostate cancer

"I'm hopeful that the decisions are more informed in terms of actual science," says Daniel Kwon, MD.


Ruben Olivares, MD

Latest:

Ruben Olivares, MD, discusses HIFU and remote prostate cancer care

Olivares cautioned that HIFU is not suitable for all patients, particularly those with more aggressive disease, for whom complete gland removal may still be necessary.


Amanda C. North, MD

Latest:

Is there a difference between MD and DO in urology?

"Osteopathic urologists were more likely to work in private practice (58.4% vs 49.8%; P = .038) and in rural/nonmetropolitan areas (16.2% vs 8.7%; P = .002)," write the authors.


Andrew G. McIntosh, MD

Latest:

Radical nephrectomy before or after systemic therapy for mRCC

Recent research has revived the controversy regarding the role of cytoreductive nephrectomy in this setting.


Brandon Daniell

Latest:

How text messaging can be a valuable tool for your practice

Here are seven ways texting can improve healthcare revenue and decrease costs.


Bryan S. Sack, MD

Latest:

Integrating video visits into urologic training

"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.


Jane Smitham

Latest:

The evolving role of microRNAs in testicular cancer management

"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.


Kyle Doherty

Latest:

New Drug Application initiated with FDA for TAR-200 for NMIBC

The NDA is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.


Chris Baird

Latest:

Online reviews are crucial to maintaining a thriving health care practice

Independent health care practices rely on online ratings and reviews to attract new patients and establish themselves as leading, recognizable providers in their community.


Cynthia Sener, MBA

Latest:

Managing your online reputation in health care

While online reviews are critical in any industry, patient expectations are simply different when it comes to health care.


Dayna R. Smerina

Latest:

Dayna R. Smerina and Amy M. Pearlman, MD, discuss their research in sexual medicine

Smerina and Pearlman discuss recent research collaborations in the field of sexual medicine.


Alicia Morgans, MD, MPH

Latest:

Exploring Recent Developments in The Treatment of Prostate Cancer

Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact clinical decision-making in prostate cancer treatment, emphasizing the importance of quality of life data and the shift from using ADT alone as standard care toward combination therapies in prostate cancer management.


Will Pizii

Latest:

Neoadjuvant chemoimmunotherapy combo shows promise in UTUC

The phase 2 study explored the combination of the PD-1 inhibitor toripalimab and chemotherapy as neoadjuvant treatment for patients with upper tract urothelial carcinoma.


University Hospitals

Latest:

Register Today! UH Urology Institute’s Fall Symposiums

University Hospitals Urology Institute is excited to announce that this coming fall, the department is hosting 2 educational courses in cutting-edge urologic specialties: female sexual health and gender care.


Robert Svatek, MD

Latest:

Robert Svatek, MD, discusses the design of the PIVOT-006 trial

“The trial is meant to define or test this agent in this population for which currently there's not an established standard of care,” says Robert Svatek, MD.


University of Miami Health System Desai Sethi Urology Institute

Latest:

Dipen Parekh, M.D. named Chief Executive Officer of the University of Miami Health System

Award-winning COO of UHealth, renowned surgeon scientist, and director of the Desai Sethi Urology Institute elevated to lead patient-focused care, biomedical research, and medical education


Allina Health Cancer Institute

Latest:

Allina Health Cancer Institute 2022 Symposium reimagines cancer care

The symposium brings together clinicians devoted to solving the disease of cancer and the many challenges associated with it.


Clint Cary, MD, MBA, MPH

Latest:

The role of surgery continues to evolve in seminoma

"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.


Tobias Nordström, MD, PhD

Latest:

Tobias Nordström, MD, on the evolving landscape of prostate cancer screening

“Another aspect is how to make this more and more complex diagnostic chain for prostate cancer work in practice, because we now have so [many] more tools than we had a decade ago,” says Tobias Nordström, MD, PhD.


Nima Sharifi, MD

Latest:

Nima Sharifi, MD, on the link between HSD3B1 and OS in prostate cancer

“We hypothesized based on prior work that specifically men with low-volume disease, if they inherit this hyperactive form of HSD3B1, they'll have shorter overall survival. It turns out that that's true,” says Nima Sharifi, MD.


Richard G. Harris, MD, FACS

Latest:

Letter: Declassifying Gleason 6 as a cancer would do more harm than good

"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.


Ralph J. Miller Jr, MD

Latest:

Ralph Miller, MD, on the state of HIFU in prostate cancer

"Most of the published data about HIFU tended to be with relatively short-term follow-up," says Ralph J. Miller Jr, MD.


Jamie Cesanek

Latest:

Abiraterone-based triplet boosts survival in de novo mCSPC

Findings from the PEACE-1 trial published in the Lancet showed that adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved overall survival in patients with de novo metastatic castration-sensitive prostate cancer.


Madhur Nayan, MD, PhD

Latest:

AI-based tool aims to optimize MRI use in prostate cancer diagnosis

"I'm excited to see how these models are going to continue to be developed and applied in clinical practice, because precision medicine is here, and I’m looking forward to it," says Madhur Nayan, MD, PhD.


Jennifer A. Linehan, MD

Latest:

Episode 3 Video: Treatment Strategies to Tackle NMIBC Heterogeneity

Panelists examine disease heterogeneity in NMIBC and discuss a balanced treatment approach that prioritizes patient quality of life and surgery effectiveness.


Sarah Murray, PhD, FACMG

Latest:

The evolving role of microRNAs in testicular cancer management

"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.

© 2025 MJH Life Sciences

All rights reserved.